‡ Lipper is an industry research firm whose rankings are based on total return performance, vary over time, and do not reflect the effects of sales charges. Past performance is not indicative of future results.
Putnam Allstate Advisor Plus
Putnam Global Health Care Subaccount
The subaccount seeks capital appreciation.
Fund description
The subaccount seeks to capitalize on the strength of the health-care sector, targeting companies of all sizes. Holdings encompass an array of industries, including pharmaceuticals, health-care services, and biotechnology. The fund seeks companies that offer strong long-term growth prospects, regardless of their size.
Sales story
Investing in the health-care sectorA dynamic sector: From biotech to pharmaceuticals, the fund seeks out companies that profit from the global demand for health care.A range of companies: The fund invests worldwide in businesses at different stages of growth, from rapidly growing newer companies to established global corporations.Actively managed: Unlike passively managed ETFs, Putnam global sector funds combine rigorous fundamental research and disciplined quantitative analysis with macroeconomic views.
Management team
- Michael J. Maguire, CFA (Investing since 2002)
Daily pricing as of 07/09/20
| with optional enhanced death benefits | ||
|---|---|---|
| Unit Value | $28.311878 | $27.447442 |
| Unit Value Change | -0.24167 | -0.234406 |
Quick facts as of 06/30/20
| Fiscal Year End | December |
| Asset Class | Putnam Allstate Advisor Plus |
| Subaccount Status | Open to new investors |
| Number of issues | 53 |
| Turnover (fiscal year end) | 86% |
| Net Assets | $145M |
| Inception Date | 05/01/98 |
Performance
Performance as of 06/30/20
| Annualized Performance | Last Quarter | Year to Date |
1 yr. | 3 yrs. | 5 yrs. | 10 yrs. | Life of subaccount |
|---|---|---|---|---|---|---|---|
| Restated performance | |||||||
| Unit Value | 14.36% | 1.46% | 17.02% | 8.18% | 3.55% | 12.07% | 5.49% |
| Standardized | 6.36% | -6.54% | 9.02% | 5.85% | 2.48% | 12.07% | 5.49% |
| With optional enhanced death benefit | |||||||
| Unit Value | 14.31% | 1.38% | 16.85% | 8.01% | 3.39% | 11.90% | 5.33% |
| Standardized | 6.31% | -6.62% | 8.85% | 5.68% | 2.32% | 11.90% | 5.33% |
| Actual performance | |||||||
| Unit Value | 14.36% | 1.46% | 17.02% | 8.18% | 3.55% | 12.07% | 4.96% |
| Standardized | 6.36% | -6.54% | 9.02% | 5.85% | 2.48% | 12.07% | 4.96% |
| With optional enhanced death benefit | |||||||
| Unit Value | 14.31% | 1.38% | 16.85% | 8.01% | 3.39% | 11.90% | 4.80% |
| Standardized | 6.31% | -6.62% | 8.85% | 5.68% | 2.32% | 11.90% | 4.80% |
Annual Performance at NAV
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|---|
| 0.83% | -2.76% | 20.31% | 39.40% | 25.60% | 6.06% | -12.77% | 13.46% | -2.19% | 28.21% |
| With optional enhanced death benefit | |||||||||
| 0.67% | -2.90% | 20.12% | 39.19% | 25.41% | 5.90% | -12.90% | 13.29% | -2.34% | 28.02% |
Restated performance
Monthly as of 06/30/20 |
|
|---|---|
| Unit Value | -0.92% |
| Standardized | -8.85% |
YTD as of 07/09/20 |
|
|---|---|
| Unit Value | 2.22% |
| Standardized | -5.78% |
With optional enhanced death benefit
Monthly as of 06/30/20 |
|
|---|---|
| Unit Value | -0.94% |
| Standardized | -8.86% |
YTD as of 07/09/20 |
|
|---|---|
| Unit Value | 2.14% |
| Standardized | -5.86% |
Unit values and performance information shown apply to the specific annuity product listed, not the underlying Putnam Variable Trust fund. This information should not be used by investors who hold an interest in Putnam Variable Trust funds through a different annuity or other variable product. The unit values and performance of other variable products that offer Putnam Variable Trust funds may be higher or lower due to product charges and expenses or other factors.
Data is historical. Past performance is no guarantee of future results. More recent returns may be less or more than those shown. Investment return and principal value will fluctuate, and you may have a gain or a loss when you sell your units.
Returns shown for the subaccounts for periods before their inception are derived from the historical performance of the underlying fund, adjusted to reflect the mortality, expense risk, and surrender charges applicable to this product and do not factor in the annual $30 contract maintenance fee. Additional riders and options for insurance-related charges will increase expenses and lower returns. Please see the prospectus for details. For a portion of the period, subaccounts may have limited expenses, without which returns would have been lower.
Variable annuities are long-term investments designed for retirement purposes. Putnam Capital Manager products are flexible-premium variable annuities held by Talcott Resolution Life, Inc., Simsbury, CT.
Putnam Allstate variable annuities are flexible-premium deferred variable annuities issued by Allstate Life Insurance Company (Allstate Life); underwritten by Allstate Distributors, L.L.C., both of Northbrook, IL; and sold through registered representatives or bank employees who are licensed insurance agents. Please check for availability in your specific state.
These policies have limitations and are sold by prospectus only. The prospectus contains details on the variable annuity, the subaccounts, contract features, fees, expenses, and other pertinent information.
Investors should carefully consider the investment objectives, risks, charges, and expenses of a fund before investing. For a prospectus containing this and other information for any variable annuity or variable life product that invests in Putnam Variable Trust funds, contact your financial advisor for a contract prospectus and prospectus for the underlying funds. You may also call Talcott Resolution at 1-800-521-0538 or Allstate at 1-800-390-1277. Read the prospectuses carefully before investing.
For the most recent month-end performance, please call Talcott Resolution at 1-800-521-0538 or Allstate at 1-800-390-1277.
Risk Characteristics as of 05/31/20
| Alpha (%) | -0.23 |
| Beta | 1.02 |
| R Squared | 0.95 |
| Standard Deviation (3 yrs.) | 14.77 |
Holdings
| UnitedHealth Group | 6.25% |
| Abbvie | 5.82% |
| Johnson&Johnson | 5.78% |
| Roche Holding Ag | 5.10% |
| Novartis Ag | 4.23% |
| Merck | 4.04% |
| Danaher Corp | 3.92% |
| Astrazeneca | 3.89% |
| Thermo Fisher Scientific | 3.32% |
| Ascendis Pharma A/S | 3.06% |
| Top 10 holdings, total: | 45.41% |
| Top 10 holdings as of 05/31/20 | |
|---|---|
| 1: UnitedHealth Group | 6.25% |
| 2: Abbvie | 5.82% |
| 3: Johnson&Johnson | 5.78% |
| 4: Roche Holding Ag | 5.10% |
| 5: Novartis Ag | 4.23% |
| 6: Merck | 4.04% |
| 7: Danaher Corp | 3.92% |
| 8: Astrazeneca | 3.89% |
| 9: Thermo Fisher Scientific | 3.32% |
| 10: Ascendis Pharma A/S | 3.06% |
| Holdings represent 45.41% of portfolio | |
| Top 10 holdings as of 04/30/20 | |
|---|---|
| 1: UnitedHealth Group | 6.30% |
| 2: Johnson&Johnson | 5.48% |
| 3: Roche Holding Ag | 5.36% |
| 4: Abbvie | 5.13% |
| 5: Novartis Ag | 4.63% |
| 6: Astrazeneca | 4.58% |
| 7: Merck | 4.50% |
| 8: Danaher Corp | 3.38% |
| 9: Thermo Fisher Scientific | 3.34% |
| 10: Ascendis Pharma A/S | 3.13% |
| Holdings represent 45.83% of portfolio | |
| Top 10 holdings as of 03/31/20 | |
|---|---|
| 1: UnitedHealth Group | 5.96% |
| 2: Novartis Ag | 5.65% |
| 3: Roche Holding Ag | 5.57% |
| 4: Merck | 5.41% |
| 5: Johnson&Johnson | 5.31% |
| 6: Abbvie | 4.91% |
| 7: Astrazeneca | 4.33% |
| 8: Pfizer | 4.30% |
| 9: Eli Lilly | 3.42% |
| 10: Ascendis Pharma A/S | 3.20% |
| Holdings represent 48.06% of portfolio | |
| Top 10 holdings as of 02/29/20 | |
|---|---|
| 1: Johnson&Johnson | 6.67% |
| 2: Novartis Ag | 5.91% |
| 3: UnitedHealth Group | 5.81% |
| 4: Roche Holding Ag | 5.49% |
| 5: Abbvie | 5.37% |
| 6: Pfizer | 4.99% |
| 7: Merck | 4.76% |
| 8: Danaher Corp | 3.84% |
| 9: Astrazeneca | 3.65% |
| 10: Eli Lilly | 3.10% |
| Holdings represent 49.59% of portfolio | |
| UNITEDHEALTH GROUP INC SEDOL 2917766 | 5.96% | NOVARTIS AG-REG SEDOL 7103065 | 5.65% | ROCHE HOLDING AG-GENUSSCHEIN SEDOL 7110388 | 5.57% | MERCK & CO. INC. SEDOL 2778844 | 5.41% | JOHNSON & JOHNSON SEDOL 2475833 | 5.31% | ABBVIE INC SEDOL B92SR70 | 4.91% | ASTRAZENECA PLC SEDOL 0989529 | 4.33% | PFIZER INC SEDOL 2684703 | 4.30% | ELI LILLY & CO SEDOL 2516152 | 3.42% | ASCENDIS PHARMA A/S - ADR SEDOL BV9G6B8 | 3.20% | DANAHER CORP SEDOL 2250870 | 3.18% | THERMO FISHER SCIENTIFIC INC SEDOL 2886907 | 3.14% | BOSTON SCIENTIFIC CORP SEDOL 2113434 | 3.07% | VERTEX PHARMACEUTICALS INC SEDOL 2931034 | 2.90% | REGENERON PHARMACEUTICALS SEDOL 2730190 | 2.86% | BIOGEN INC SEDOL 2455965 | 2.79% | BAXTER INTERNATIONAL INC SEDOL 2085102 | 2.29% | ABBOTT LABORATORIES SEDOL 2002305 | 2.24% | CIGNA CORP SEDOL BHJ0775 | 2.22% | INTUITIVE SURGICAL INC SEDOL 2871301 | 2.19% | HUMANA INC SEDOL 2445063 | 2.16% | GILEAD SCIENCES INC SEDOL 2369174 | 1.86% | AMGEN INC SEDOL 2023607 | 1.69% | LONZA GROUP AG-REG SEDOL 7333378 | 1.66% | MCKESSON CORP SEDOL 2378534 | 1.40% | DAIICHI SANKYO CO LTD SEDOL B0J7D91 | 1.39% | IRONWOOD PHARMACEUTICALS INC SEDOL B3MZ6K5 | 1.35% | CENTENE CORP SEDOL 2807061 | 1.28% | MYLAN NV SEDOL BVFMFG8 | 1.05% | SANOFI SEDOL 5671735 | 0.97% | TAKEDA PHARMACEUTICAL CO LTD SEDOL 6870445 | 0.92% | SAREPTA THERAPEUTICS INC SEDOL B8DPDT7 | 0.87% | MIRATI THERAPEUTICS INC SEDOL BBPK0J0 | 0.86% | BIO-RAD LABORATORIES-A SEDOL 2098508 | 0.86% | SEATTLE GENETICS INC SEDOL 2738127 | 0.83% | IDEXX LABORATORIES INC SEDOL 2459202 | 0.79% | ASTELLAS PHARMA INC SEDOL 6985383 | 0.58% | BAYER AG-REG SEDOL 5069211 | 0.57% | ACCELERON PHARMA INC SEDOL BDGTXQ8 | 0.53% | BLUEPRINT MEDICINES CORP SEDOL BWY52P3 | 0.45% | TERUMO CORP SEDOL 6885074 | 0.44% | LIFESCI ACQUISITION CORP SEDOL BLCH8B2 | 0.36% | ROCKET PHARMACEUTICALS INC SEDOL BDFKQ07 | 0.36% | TREASURY BILL 00.0000 07/09/2020 | 0.26% | TREASURY BILL 00.0000 08/13/2020 | 0.14% | TREASURY BILL 00.0000 04/09/2020 | 0.10% | TREASURY BILL 00.0000 06/04/2020 | 0.09% | CHF/USD 06/17/2020 JPMCB | 0.04% | JPY/USD 05/20/2020 GSFX | 0.04% | GBP/USD 06/17/2020 SSBT | 0.03% | TREASURY BILL 00.0000 07/16/2020 | 0.02% | TREASURY BILL 00.0000 07/23/2020 | 0.02% | EUR/USD 06/17/2020 SSBT | 0.02% | JPY/USD 05/20/2020 CSI-FX | 0.01% | JPY/USD 05/20/2020 UBS | 0.00% | DKK/USD 06/17/2020 CITI | 0.00% | JPY/USD 05/20/2020 BCAP-FX | 0.00% | NEURALSTEM INC SERIES K COMMON STOCK PURCHASE WARRANT | 0.00% | JPY/USD 05/20/2020 SSBT | -0.00% | ILS/USD 04/16/2020 SSBT | -0.00% | CHF/USD 06/17/2020 SSBT | -0.00% | EUR/USD 06/17/2020 BCAP-FX | -0.01% | JPY/USD 05/20/2020 JPMCB | -0.02% | NZD/USD 04/15/2020 JPMCB | -0.02% | GBP/USD 06/17/2020 GSFX | -0.03% | AUD/USD 04/15/2020 JPMCB | -0.05% | EUR/USD 06/17/2020 BANKAM | -0.05% | AUD/USD 04/15/2020 RBSF | -0.16% |
| JOHNSON & JOHNSON SEDOL 2475833 | 6.61% | UNITEDHEALTH GROUP INC SEDOL 2917766 | 6.44% | NOVARTIS AG-REG SEDOL 7103065 | 5.96% | MERCK & CO. INC. SEDOL 2778844 | 5.52% | ROCHE HOLDING AG-GENUSSCHEIN SEDOL 7110388 | 5.41% | ABBVIE INC SEDOL B92SR70 | 5.37% | AMGEN INC SEDOL 2023607 | 4.44% | DANAHER CORP SEDOL 2250870 | 3.96% | ASTRAZENECA PLC SEDOL 0989529 | 3.75% | BOSTON SCIENTIFIC CORP SEDOL 2113434 | 3.48% | PFIZER INC SEDOL 2684703 | 3.27% | ABBOTT LABORATORIES SEDOL 2002305 | 3.09% | ELI LILLY & CO SEDOL 2516152 | 2.98% | HUMANA INC SEDOL 2445063 | 2.62% | MEDTRONIC PLC SEDOL BTN1Y11 | 2.59% | VERTEX PHARMACEUTICALS INC SEDOL 2931034 | 1.98% | GLAXOSMITHKLINE PLC SEDOL 0925288 | 1.78% | THERMO FISHER SCIENTIFIC INC SEDOL 2886907 | 1.77% | INTUITIVE SURGICAL INC SEDOL 2871301 | 1.71% | CSL LTD SEDOL 6185495 | 1.55% | REGENERON PHARMACEUTICALS SEDOL 2730190 | 1.50% | NOVO NORDISK A/S-B SEDOL BHC8X90 | 1.49% | BAXTER INTERNATIONAL INC SEDOL 2085102 | 1.46% | CIGNA CORP SEDOL BHJ0775 | 1.35% | SANOFI SEDOL 5671735 | 1.21% | DAIICHI SANKYO CO LTD SEDOL B0J7D91 | 1.14% | ASCENDIS PHARMA A/S - ADR SEDOL BV9G6B8 | 1.14% | MCKESSON CORP SEDOL 2378534 | 1.07% | ALLERGAN PLC SEDOL BY9D546 | 1.07% | EDWARDS LIFESCIENCES CORP SEDOL 2567116 | 1.07% | BIOGEN INC SEDOL 2455965 | 0.96% | BRISTOL-MYERS SQUIBB CO SEDOL 2126335 | 0.94% | GILEAD SCIENCES INC SEDOL 2369174 | 0.94% | IDEXX LABORATORIES INC SEDOL 2459202 | 0.84% | BAYER AG-REG SEDOL 5069211 | 0.79% | BECTON DICKINSON AND CO SEDOL 2087807 | 0.79% | LONZA GROUP AG-REG SEDOL 7333378 | 0.75% | SEATTLE GENETICS INC SEDOL 2738127 | 0.70% | SAREPTA THERAPEUTICS INC SEDOL B8DPDT7 | 0.65% | TAKEDA PHARMACEUTICAL CO LTD SEDOL 6870445 | 0.50% | CVS HEALTH CORP SEDOL 2577609 | 0.49% | ILLUMINA INC SEDOL 2613990 | 0.34% | NEXTCURE INC SEDOL BJL3CL5 | 0.31% | ROCKET PHARMACEUTICALS INC SEDOL BDFKQ07 | 0.30% | ANTHEM INC SEDOL BSPHGL4 | 0.28% | Y-MABS THERAPEUTICS INC SEDOL BG31GH0 | 0.27% | UNIQURE NV SEDOL BJFSR88 | 0.27% | TREASURY BILL 00.0000 04/09/2020 | 0.08% | TREASURY BILL 00.0000 06/04/2020 | 0.08% | EUR/USD 03/18/2020 BANKAM | 0.04% | GBP/USD 03/18/2020 GSFX | 0.02% | AUD/USD 01/15/2020 JPMCB | 0.02% | NZD/USD 01/15/2020 UBS | 0.01% | GBP/USD 03/18/2020 JPMCB | 0.01% | EUR/USD 03/18/2020 BCAP-FX | 0.00% | EUR/USD 03/18/2020 SSBT | 0.00% | CAD/USD 01/15/2020 CITI | 0.00% | ILS/USD 01/15/2020 SSBT | 0.00% | JPY/USD 02/19/2020 BCAP-FX | 0.00% | JPY/USD 02/19/2020 UBS | 0.00% | MDCO 20200117 P 28.00BCBP | 0.00% | MDCO 20200117 P 35.00BCBP | 0.00% | NEURALSTEM INC SERIES K COMMON STOCK PURCHASE WARRANT | 0.00% | DKK/USD 03/18/2020 CITI | -0.00% | JPY/USD 02/19/2020 CSI-FX | -0.00% | JPY/USD 02/19/2020 JPMCB | -0.00% | EUR/USD 03/18/2020 JPMCB | -0.00% | JPY/USD 02/19/2020 GSFX | -0.00% | GBP/USD 03/18/2020 BCAP-FX | -0.05% | CHF/USD 03/18/2020 JPMCB | -0.06% |
Portfolio Composition as of 05/31/20
| Common stock | 96.61% |
| Cash and net other assets | 2.94% |
| Convertible preferred stock | 0.45% |
Consider these risks before investing: International investing involves currency, economic, and political risks. Emerging-market securities carry illiquidity and volatility risks. Investments in small and/or midsize companies increase the risk of greater price fluctuations. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices, or procedures, and changes in governmental and private payment systems. The fund concentrates on a limited group of industries and is non-diversified. Because the fund may invest in fewer issuers than a diversified fund, it is vulnerable to common economic forces and may result in greater losses and volatility. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. The use of short selling may result in losses if the securities appreciate in value. Risks associated with derivatives include increased investment exposure (which may be considered leverage) and, in the case of over-the-counter instruments, the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. The value of investments in the fund’s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general economic, political, or financial market conditions; investor sentiment and market perceptions; government actions; geopolitical events or changes; and factors related to a specific issuer, geography, industry, or sector. These and other factors may lead to increased volatility and reduced liquidity in the fund’s portfolio holdings. Our investment techniques, analyses, and judgments may not produce the outcome we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund’s other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund. Variable annuities are long-term investments designed for retirement purposes. Withdrawals prior to age 59 1/2 may be subject to a 10% IRS penalty.
Top Industry Sectors as of 05/31/20
| Pharmaceuticals | 37.23% |
|---|---|
| Biotechnology | 23.42% |
| Health Care Providers & Services | 15.26% |
| Health Care Equipment & Supplies | 13.34% |
| Life Sciences Tools & Services | 6.91% |
| Cash and net other assets | 2.94% |
| Health Care Technology | 0.57% |
| Diversified Financial Services | 0.33% |
0
Country Allocation as of 05/31/20
| United States | 70.20% |
|---|---|
| Switzerland | 11.03% |
| United Kingdom | 5.67% |
| Denmark | 4.70% |
| Japan | 3.64% |
| Cash and net other assets | 2.94% |
| France | 0.92% |
| Australia | 0.84% |
| Germany | 0.06% |
0
Expenses
Sales Charges/Fees
| Breakpoint | Sales Charge | Dealer Allowance | CDSC Liab |
|---|---|---|---|
| $0 - $0 | 0.00% | 0.00% | N |
CDSC
| Year | Percent |
|---|---|
| 1 | 8.00% |
| 2 | 8.00% |
| 3 | 8.00% |
| 4 | 7.00% |
| 5 | 6.00% |
| 6 | 5.00% |
| 7 | 4.00% |
| 8 | 3.00% |
| 9+ | 0.00% |